Drug · DIN 02304619
PRIVIGEN
ALSO KNOW AS IMMUNE GLOBULIN (HUMAN)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 8, 2009; first marketed January 8, 2009.
- Drug Identification Number (DIN)
- 02304619
- Company (DIN owner)
- Csl Behring Canada IncOttawa, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Immunoglobulins, normal human, for intravasc. adm. J06BA02
- Class
- Human
- Record last updated
- August 26, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IMMUNOGLOBULIN (HUMAN) | 10 % |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 9, 2008: NOC 9282New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “privigen”. A notice may cover another product or only some lots: read it to see what it covers.
- Privigen: Series of adverse reactionsDecember 21, 2023 · Drugs · Adverse reaction · Type II
- Privigen: Series of adverse reactionsDecember 1, 2022 · Drugs · Adverse reaction · Type II
- Privigen, Immune Globulin Intravenous (Human) - Association of Hemolysis Following Administration and Related Labeling Update - Notice to HospitalsJune 1, 2012 · Biologic or vaccine
- Privigen, Immune Globulin Intravenous (Human) - Association of Hemolysis Following Administration and Related Labeling Update - For the PublicJune 1, 2012 · Biologic or vaccine